A team of collaborators drawn from Harvard, Johnson & Johnson and other groups published results from a preclinical animal study Thursday afternoon that underscores the potential for developing the world's first HIV vaccine.
Vertex Pharmaceuticals won the FDA's blessing to market a new combination therapy for cystic fibrosis, clearing the way for a drug key to the company's future as it moves away from antiviral treatments.
Dutch drug developer Kiadis Pharma pulled in €32.7 million ($36.3 million) in a European IPO, raising cash to develop a pair of stem cell treatments.
Ex-Pharmacyclics CEO Richard Miller is looking for a second act in biotech with his startup Corvus Pharmaceuticals.
Last year, Gilead Sciences paid $125 million for a ticket promising a speedy FDA review. Now the Big Biotech is cashing it in, submitting a combination HIV treatment for approval and lining up for a truncated regulatory process.
Fresh off a landmark $1 billion deal to buy into Juno's immuno-oncology pipeline, fast-growing Celgene has inked another contract to buy up Merck's sprawling old campus in Summit, NJ.
Four years ago, Pfizer spent $56 million to bag Icagen and add its ion channel R&D platform and pipeline in North Carolina with its pain drug development arm in the U.K. But yesterday the pharma giant spun the platform back out to a small contract research group in Cambridge, MA, called XRPro Sciences, which will now combine its operations into an expanded research services operation that will cater to the biopharma industry.
Biogen has taken another big step in building its new gene therapy operations, inking a comprehensive $1 billion-plus partnership--including an upfront of $124 million--with the Florida-based biotech AGTC on a few new programs for rare eye diseases.
In this week's EuroBiotech Report, Actelion bet €30 million ($33 million) on the potential of synthetic carbohydrate vaccines, becoming the majority shareholder in a biotech created to develop assets discovered at the Max Planck Society and giving it exposure to the vaccine field without interfering with its core business. And more.
Pharma Two B has stepped up its hunt for financing after its Parkinson's disease combination drug came through a Phase IIb trial. The data have given Pharma Two B the confidence to start talking up a possible IPO or partnership deal as it moves toward gathering the cash needed for a pivotal study.
Immunocore has added another string to its collaboration with Eli Lilly. The deal is intended to show whether there is value in combining Immunocore's lead T cell receptor-based therapy with galunisertib and merestinib in patients with metastatic cutaneous and uveal melanomas.
Cell Therapy has posted positive data from a Phase II trial of its topical regenerative medicine to repair severe tendon injury. And with mid-stage data in the bag and a sizable potential market awaiting commercialization of the product, the regenerative medicine specialist is now assessing its partnership options.
The FDA has opted to delay its review of cobimetinib in order to give regulators more time to consider additional Phase III data provided by Genentech.
More than a year after announcing plans to spin out its drug business, Baxter has begotten Baxalta, a $6 billion standalone company with plans to elbow its way into the upper ranks of biopharma.
You can score another setback for Roche's star-crossed attempt to develop a new drug for Alzheimer's. Roche partner Evotec reported that their drug sembragiline failed a Phase IIB study.
Xenon Pharmaceuticals' Teva-partnered treatment for osteoarthritis pain missed its goals in a Phase IIb trial, a failure the biotech believes won't derail the drug's development in other indications.
FierceBiotech Radio on the cost of CAR-T, the future of Zoetis, and gentrification in Kendall Square
FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss the week's biggest news in biopharma, including Celgene's big-money partnership with Juno Therapeutics, buyout rumors surrounding Zoetis, and the latest Big Pharma to move into Cambridge, MA.
Purdue Pharma has canceled an all-important discussion with FDA advisers about its latest spin on OxyContin less than a week ahead of the scheduled meeting, an uncommon move the company said will ultimately improve its odds of success.
AstraZeneca CEO Pascal Soriot made it clear back in early 2014 that he planned to spin off a big chunk of the company's anti-infectives pipeline along with the neurosciences side of R&D. And now more than a year later the pharma company has completed the task, hatcheting down a once large group of researchers and birthing a small biotech with its own pipeline of antibiotics and a core group of investigators.